Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
Celyad Oncology SA (CYAD) is a biotechnology company headquartered in Mont‑Saint‑Guibert, Belgium, with shares admitted to trading on Euronext. Its regulatory news flow provides detailed insight into the company’s strategic focus on managing and licensing its intellectual property portfolio, including proprietary technology platforms, as well as its capital structure and major shareholdings.
News about Celyad Oncology frequently covers decisions that affect its operational profile and financial position. For example, the company has announced the discontinuation of its research and development activities and a significant reduction in its R&D workforce due to limited cash resources, stating that it will concentrate on the management and licensing of its intellectual property portfolio. Other releases describe the divestiture of its research facility’s equipment and office furniture under an asset purchase agreement, which management expects to extend the company’s cash runway.
Investors following CYAD news can also track financing transactions and ownership changes. The company has reported a private placement financing with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group, and has issued multiple transparency notifications detailing when this shareholder has crossed voting‑rights thresholds. In addition, Celyad Oncology regularly publishes updates on the total number of shares and voting rights, including the impact of double voting rights on certain registered shares.
This news page is useful for readers who want to monitor regulatory announcements on Celyad Oncology’s strategic decisions, capital increases, asset sales, major shareholdings and voting‑rights structure. By reviewing these updates, users can follow how the company’s focus on intellectual property, its financing arrangements and its ownership profile evolve over time.
Celyad Oncology (Euronext: CYAD) received a transparency notification dated November 20, 2025, reporting that CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has passively crossed above the 65% threshold.
As of the threshold crossing on November 14, 2025, CFIP CLYD (UK) Limited holds 49,050,641 voting rights, equal to 67.77% of the 72,383,166 voting rights denominator. This increase reflects double voting rights applied from 14 November 2025 to shares issued in the 14 November 2023 private placement, bringing CFIP's shares with double voting rights to 22,858,654.
The notification details the full ownership chain and states Fortress can exercise voting rights via its investment advisers without client instruction. The crossing is described as a passive upward movement above the 65% threshold.
Celyad Oncology (Euronext: CYAD) reported its updated share and voting-rights totals as of 14 November 2025.
- 14,903,846 shares of CFIP CLYD (UK) Limited now carry double voting rights.
- Total number of shares: 44,761,905.
- Total voting rights after the change: 72,383,166.
- Total share capital: €9,216,154.53.
- Attributed warrants: 3,856,134, producing a diluted share count of 48,618,039 and diluted voting rights of 76,239,300.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on disclosure of major participations.
Celyad Oncology (Euronext: CYAD) has announced the divestment of its research facility in Mont-Saint-Guibert, Belgium. The company will sell the facility's equipment and office furniture for €3 million.
The transaction, subject to customary conditions, is expected to close in Q4 2025. This strategic move is anticipated to extend the company's cash runway by approximately three quarters, reaching into Q3 2026.
Celyad Oncology (Euronext: CYAD) reported its financial results for H1 2025, showing a deteriorating financial position. The company's cash position dropped to €0.8 million as of June 30, 2025, compared to €4.2 million at the end of 2024. The net loss increased to €3.7 million (€0.09 per share) from €3.0 million (€0.07 per share) in H1 2024.
R&D expenses increased by €0.6 million to €2.1 million, primarily due to higher IP costs and catheter development expenses. G&A expenses remained stable at €1.7 million. The company projects its current cash position will only fund operations into Q4 2025, indicating potential liquidity concerns.
Celyad Oncology (CYAD) announced a significant change in its voting rights structure as CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has passively crossed below the 60% threshold. The company now holds 34,146,795 voting rights, representing 59.41% of Celyad Oncology's total voting rights.
The change resulted from the maturation of double voting rights on shares issued during the September 2023 private placement. CFIP CLYD (UK) Limited's 7,954,808 shares now carry double voting rights, but due to another shareholder's larger stake also receiving double voting rights, their overall percentage decreased.
Celyad Oncology (Euronext: CYAD) has announced an update to its voting rights structure. As of September 4, 2025, the company reports that 3,849,040 registered shares now benefit from double voting rights. The company's share capital stands at €9,216,154.53, with a total of 44,761,905 shares outstanding, comprising 32,044,490 shares with single voting rights and 12,717,415 shares with double voting rights.
The total number of voting rights has reached 57,479,320. Additionally, there are 3,856,134 warrants outstanding, which could potentially create an equal number of shares with voting rights. On a fully diluted basis, the total number of shares would be 48,618,039 with 61,335,454 voting rights.
[]Celyad Oncology (Euronext: CYAD) has announced the discontinuation of its research and development activities and a significant reduction in its R&D workforce due to limited cash resources. The company will shift its focus to managing and licensing its intellectual property portfolio in CAR-T cell therapy.
CEO Matt Kane emphasized the company's commitment to supporting employees through the transition while exploring potential collaborations to leverage their IP assets. With cash resources expected to fund operations only until mid Q4 2025, Celyad is assessing strategic options and plans to sell remaining assets while maintaining strict cost-containment measures.
Celyad Oncology (Euronext: CYAD) has received a significant transparency notification from Fortress Investment Group LLC dated August 11, 2025. The notification reveals that CFIP CLYD (UK) Limited, a Fortress affiliate, has increased its voting rights to 32,691,987 shares, representing 60.96% of Celyad Oncology's total voting rights.
The threshold crossing occurred on August 5, 2025, following a capital increase where CFIP CLYD (UK) Limited received 3,333,333 additional shares. The transaction increased their holdings from their previous position of 29,358,654 voting rights, surpassing the statutory threshold of 60%.
Celyad Oncology (Euronext: CYAD) has announced changes to its share capital and voting rights structure following the issuance of 3,333,333 new shares to a Fortress Investment Group affiliate on August 5, 2025. The company's share capital has increased to €9,216,154.53, now represented by 44,761,905 total shares.
The updated structure includes 35,893,530 shares with single voting rights and 8,868,375 shares with double voting rights, totaling 53,630,280 voting rights. Additionally, there are 3,856,134 attributed warrants that could potentially create an equal number of shares with voting rights.
Celyad Oncology (Euronext: CYAD) has secured a €1 million private placement through a subscription agreement with CFIP CLYD (UK) Limited (Fortress). The deal involves issuing 3,333,333 new ordinary shares at €0.30 per share, representing a 15% discount to the 10-day VWAP on Euronext Brussels.
Following the transaction, expected to close around August 5, 2025, Fortress will hold approximately 58.51% of the company's shares. The proceeds will support working capital and general corporate purposes, extending Celyad's cash runway from mid-Q3 2025 to mid-Q4 2025, providing additional time to evaluate strategic options for strengthening its balance sheet.
FAQ
What is the market cap of CYAD (CYAD)?
